Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Avenue Therapeutics Inc
ATXI
Healthcare
Biotechnology
Drug Manufacturers - Specialty & Generic
Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. The Company is developing three assets including AJ201, an asset for spinal and bulbar muscular atrophy; BAER-101, an oral small molecule selective Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAA a2, a3) receptor positive...
allosteric modulator for central nervous system (CNS) diseases; and IV tramadol, which is in phase III clinical development for the management of acute postoperative pain in adults in a medically supervised healthcare setting. AJ201 is a pleiotropic small molecule that is designed to modify multiple mechanisms including degradation of the abnormal AR protein and stimulation of Nrf1 and Nrf2, which are involved in protecting cells form oxidative stress which can lead to cell death. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:ATXI)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
Next
(146)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on Jan 24, 2025 10:15am
Big buying going on for this stock this morning.
It's a good one to buy and hold for the year.
(292)
•••
whytestocks
X
Post by
whytestocks
on Jun 20, 2024 9:15pm
Avenue Therapeutics to Present at the H.C. Wainwright 5th An
BREAKING NEWS: $ATXI Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual ConferenceMIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq
...more
(70)
•••
Iseneschal
X
Post by
Iseneschal
on May 08, 2024 12:04pm
ATXI.... It's a "new game" post RS
I'll call this ........... "The Next One" ; )
(292)
•••
whytestocks
X
Post by
whytestocks
on Apr 29, 2024 5:30pm
Avenue Therapeutics Announces Exercise of Warrants for $4.4
Breaking News: $ATXI Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross ProceedsMIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (&
...more
(70)
•••
Iseneschal
X
Post by
Iseneschal
on Mar 09, 2023 12:35pm
ATXI...... Re-read this NR again !
Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates 2023-03-08 13:01 ET - News Release MIAMI, March 08, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc
...more
(70)
•••
Iseneschal
X
Post by
Iseneschal
on Mar 09, 2023 12:29pm
ATXI.....broke $1.18 to the upside.... Bullish!
On watch for continuation to N.H.O.D....... Lets see if it goes? Cheers !
(70)
•••
Iseneschal
X
Post by
Iseneschal
on Mar 09, 2023 10:39am
ATXI .... In PB mode support at $1.10
No position
(70)
•••
Iseneschal
X
Post by
Iseneschal
on Mar 09, 2023 7:05am
ATXI .... On watch for yesterdays NR.....no position
Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates 2023-03-08 13:01 ET - News Release MIAMI, March 08, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 10, 2022 4:10pm
New Press Release - Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases (“CNS”), today reported financial...
read article.
(70)
•••
Iseneschal
X
Post by
Iseneschal
on Nov 09, 2022 2:58pm
ATXI ....The Chasers are chasing ; )
Syonara
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 08, 2022 8:30am
New Press Release - Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A α2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders
NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system (“CNS”) diseases, today announced the...
read article.
(70)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 25, 2022 3:24pm
ATXI ..... Read my last post...Cheers !
Still here
(70)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 21, 2022 3:43pm
ATXI ....still in this and not going away!
Have a great weekend... Cheers !
(70)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 21, 2022 11:51am
ATXI .....next target is over $4
JMHO
(70)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 18, 2022 10:34am
ATXI ..... this is going to be my finest hour !!!!!!
Wait for it ; )
Prev
1
2
3
4
5
6
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Results Beyond Expectation for First Completed Drill Hole; up to 8 g/t Gold in Getchell Trend
Coniagas Progresses Drill Program on Near Surface and Extensive Ni-Cu-Co-PGM Mineralization Zones
Tribe Showcases Resilience Amidst Trade & Tariff Uncertainty & Unveils Proprietary Property Inspection Tool